Innovative Solutions for Biotechnology Challenges
Geneovese, Inc.
We are focused on innovating anti-cancer cell-targeted therapeutics that deliver medicines to where you need them.
We believe patients and their families desperately need and deserve better, more effective treatments for cancer: at any age, at any stage.
Our Vision
We've identified a way to improve the stability, potency and tolerability of cell-targeted therapeutics using a new class of linker-payloads.
We're leveraging prior clinical research knowledge and a next-generation payload architecture that expands the therapeutic window.
We hope to bring new medicines to market for patients who have limited or ineffective treatment options available.
Target Indications
We're evaluating oncology indications where current treatments and classic targeted therapies underperform, and where our platform has a clear mechanistic advantage.
Our technology focuses on the controlled release of cell-targeted therapeutics, unlocking better tolerability with improved efficacy. We aim to deliver the most efficacious solutions in the oncology space.
Janet Little
Geneovese Inc.
Founder, CEO and Inventor
Geneovese Inc. is a small female-founded and female-led biotech company based in Redmond, Washington.
We believe small companies doing big work will usher in the next wave of innovative medicines.
Janet has been working on helping cancer patients for the better part of a decade by working to advance Antibody Drug Conjugates.
Get in Touch
Geneovese, Inc
(Delaware C-Corp)
Janet Little
Redmond, WA 98033
Represented by COJK PLLC: Seattle Intellectual Property (IP) Law Firm
